CClinicalTrials.gg
CompletedNCT05811052Updated May 13, 2024

The Effect of Suboccipital Release Technique in Individuals With Anxiety

An interventional study of Suboccipital Release Technique and Sham Suboccipital Release in Anxiety, Trapezius Muscle Strain and Pain, sponsored by Abant Izzet Baysal University. Completed at 1 site in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-13.

Sponsored by Abant Izzet Baysal University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Mar 2022, registered Mar 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the immediate effect of the suboccipital release technique on trapezius muscle pain threshold, muscle activation, and anxiety level in individuals with anxiety.Thirty-six people with anxiety symptoms were included in the study. These people were divided into two groups, 18 control group and 18 treatment group. Upper trapezius muscle pain threshold, muscle activation and anxiety levels were evaluated. The experimental group received a single session of suboccipital release technique. The control group received a single session of sham suboccipital release. The evaluations were performed before and immediately after the treatment.The suboccipital release technique can increase the trapezius muscle upper part pain threshold and concentric muscle activation immediately after the application in individuals with anxiety.

02

Conditions studied

  • Anxiety
  • Trapezius Muscle Strain
  • Pain

Browse trials for

03

In context

Anxiety Disorders

4,868 studies on the registry are indexed under Anxiety Disorders; 1,390 are open to participants now.

This study's enrollment of 36 is below the median of 80 across 4,174 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Abant Izzet Baysal University is the lead sponsor of 242 studies on the registry; 64 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Being over the age of 18
  • Agree to participate the study

Exclusion criteria

Exclusion Criteria:

  • Use psychiatric, analgesic and antispasmodic drugs
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Suboccipital Release Group

    Other: Suboccipital Release Technique

  • Sham comparator
    Control Group

    Other: Sham Suboccipital Release

Interventions

  • OtherSuboccipital Release Technique

    The suboccipital release technique was applied to the participants in the experimental group by an experienced practitioner who had received osteopathy training. The individual lay in the supine position, and the practitioner applied the relaxation technique by placing his hands on the patient's nape-atlantooccipital joint. The application was continued until the relaxation of the muscles under the hand of the practitioner.

  • OtherSham Suboccipital Release

    The participants in the control group were given a sham application by touching the hands of the therapist on the nape of the neck and waiting for a while.

06

What researchers measure

Primary outcomes

  1. The State- Trait Anxiety Inventory

    The State Anxiety Scale includes questions that require the respondent to answer by taking into account his/her current feelings, while the Trait Anxiety Scale includes questions that evaluate how the respondent feels in general. It is a 4-point Likert scale. The total score obtained from both scales is minimum 20 and maximum 80. A high score indicates a high level of anxiety and a low score indicates a low level of anxiety.

    Time frame: Change from Baseline Anxiety Level at immediately after treatment

  2. Pain Assessment

    Pain threshold was evaluated with a manual algometer device. The midpoint of the upper trapezius muscle and the tender point with the highest pain were marked.

    Time frame: Change from Baseline anxiety level at Immediately After treatment

  3. Surface Electromyography Measurements

    Maximum Voluntary Concentration (MVC) value was then measured. For the MVC value, individuals were asked to push their shoulders up (in the upward direction) against a manual resistance for 5 seconds. The measurement was repeated 3 times and 2 rests were taken after each measurement. The highest of the values was used for normalization. Afterwards, the subjects were asked to perform active shoulder elevation (concentric activity) for 3 seconds and return to neutral position for 3 seconds with the metronome. For normalization, % MVC and function % MVC values were calculated using the values recorded for all recordings.

    Time frame: Change from Baseline anxiety level at Immediately After treatment

  4. Hospital Anxiety and Depression Scale

    Toplam 14 maddeden oluşan (/ Anksiyete ve 7 Depresyon sorusu). 4'lü Likert tipinde bir ölçektir. 0-3 arasında bir puanlama yapılırç 0-1 puan hasta olmayan, 2 puan sınırda hasta, 2-3 puan ağır hasta olarak değerlendirilir.

    Time frame: Baseline

Secondary outcomes

  1. Cranial Rhythm

    Individuals were placed on the treatment bed in the supine position. The therapist touched the individual's skull and recorded the number of cycles received in one minute.

    Time frame: Change from Baseline anxiety level at Immediately After treatment

07

Study locations

1 site
  • sezen Tezcan
    Bolu, Merkez 14200, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05811052
Lead sponsor
Abant Izzet Baysal University
Responsible party
Sezen Tezcan (Assist. Prof, Abant Izzet Baysal University) — Principal investigator
First posted
Apr 13, 2023
Start date
Mar 1, 2022
Primary completion
Jul 6, 2022
Completion
Feb 28, 2023
Last update
May 13, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion